ESRP1 and cancer: For example, the fraction of tumors with detectable ESRP1 expression increased from 35.1% in ERG-negative cancers to 42.8% in ERG-positive cancers and with detectable ESRP2 expression from 36.7% in ERG-negative cancers to 51.6% in ERG-positive cancers (Fig. 2).